Search clinical trials for: GSK573719 GW642444 62.5/25

Total 74 results

GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, United States, Bulgaria, Estonia, United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

Safety, Blood Levels and Effects of GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Ukraine, Slovakia
GlaxoSmithKline

Completed

Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

Pulmonary Disease, Chronic Obstructive

Germany, Estonia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
NYU Langone Health

Completed

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

COVID-19

United States
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

Liver Diseases

Japan
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Aclaris Therapeutics, Inc.

Completed

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis (SK)

United States
Cairo University
Norhan Abdel Aleem Ali; Hagar hassanein refaee; Ahmed Abdullah Fathi Mohamed...

Completed

A Comparative Study on Three Different Doses of Intrathecal Hyperbaric Prilocaine With Fentanyl for Optimal Dose to be Used in Elderly Patients Undergoing Day Case Lower Abdominal and Urologic Surgeries.

Three Different Doses of Intrathecal Hyperbaric Prilocaine With Fentanyl

Egypt
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Solid Tumor | Idiopathic Pulmonary Fibrosis(IPF)

China
Mesoblast, Inc.

Completed

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction (AMICI)

Acute Myocardial Infarction
UCB Pharma

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

United States, Australia, Canada, Brazil, Mexico
UCB Pharma

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

United States, Canada, Finland, France, Israel, Russian Federation, Serbia, Tunisia
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

COPD

Mexico
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
IntegoGen, LLC

Withdrawn

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Alimentiv Inc.
Abbott

Terminated

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Ulcerative Colitis
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Sweden, New Zealand, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
GlaxoSmithKline

Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Ukraine, United States, Estonia, South Africa, Sweden, Norway, Russian Federation, Korea, Republic of
GlaxoSmithKline

Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Pulmonary Disease, Chronic Obstructive

Argentina, France, Germany, Russian Federation, Ukraine, Italy, Norway
Creighton University

Withdrawn

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

Hypertension

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Androxal

Bioequivalence

United States
Statens Serum Institut

Completed

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

Tuberculosis

Netherlands
AstraZeneca
St. John's Research Institute

Completed

A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components (MARS)

Primary Hypertension

India
GlaxoSmithKline

Completed

A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies

Metabolic, Cardiovascular

United Kingdom
University of Wisconsin, Madison
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol

Focus of the Study: Normal Volunteers

United States

3

Subscribe